A plain-language guide

Huntington disease

What is known, what is still uncertain, and what is actively debated, written plainly, and built only from published medical research.

Early map · 12 sourced statements Every statement names its source Updated 2026-06-11
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. Huntington disease is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What it is

Huntington disease is an inherited (autosomal dominant) neurodegenerative brain disease that progressively affects movement, thinking, and behaviour, with onset usually in adulthood. It is caused by an expanded CAG repeat in the HTT gene.

Signs and symptoms

Chorea

Chorea, brief involuntary jerking or writhing movements, is the most common movement-disorder feature of Huntington disease.

Limited evidenceSource: ORPHA:399
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:29996061
Notesplain_language confirmed from PMID:29996061 via curation 2026-06-11.
Last reviewed2026-06-11

Depression

Depression is one of the significant behavioural features of Huntington disease and affects quality of life.

Limited evidenceSource: ORPHA:399
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:27296904
Notesplain_language confirmed from PMID:27296904 via curation 2026-06-11.
Last reviewed2026-06-11

Irritability

Irritability is a common behavioural feature of Huntington disease.

Limited evidenceSource: ORPHA:399
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:27296904
Notesplain_language confirmed from PMID:27296904 via curation 2026-06-11.
Last reviewed2026-06-11

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

Deutetrabenazine

Deutetrabenazine is an oral medicine that reduces chorea in Huntington disease by inhibiting the vesicular monoamine transporter 2 (VMAT2). It treats the symptom, not the underlying disease.

Used to help with: Chorea.

Limited evidenceSource: PMID:29497277
The source text this rests on
“Deutetrabenazine was recently approved for the treatment of chorea in Huntington's disease (HD) and is the first deuterated medication that has been US Food and Drug Administration (FDA)-approved for therapeutic use.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:29497277 via curation 2026-06-11
Last reviewed2026-06-11

Tetrabenazine

Tetrabenazine is the original vesicular monoamine transporter 2 (VMAT2) inhibitor used to reduce chorea in Huntington disease, treating the symptom rather than the disease itself.

Used to help with: Chorea.

Limited evidenceSource: PMID:29996061
The source text this rests on
“Deutetrabenazine is the first deuterated drug and second drug after tetrabenazine, the classic vesicular monoamine transporter type 2 (VMAT2) inhibitor, to receive approval for the treatment of chorea associated with HD.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:29996061 via curation 2026-06-11
Last reviewed2026-06-11

Turn this into questions for your doctor

The hardest part is often knowing what to ask. PatientLead Health helps families turn what is on this page into the right questions for their care team.

Prepare for your appointment with PatientLead Health →

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.

Where this comes from

This guide is built from 3 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

ORPHA:399 · Orphanet/HPO annotations for Huntington disease
PMID:29497277 · Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
PMID:29996061 · Deutetrabenazine for the treatment of Huntington's chorea.